Drug Profile

Rucaparib - pharmaand GmbH

Alternative Names: AG-014699; AG-14699; CO-338; PF-01367338; PF-1367338; Rubraca; Rucaparib phosphate - pharmaand GmbH

Latest Information Update: 19 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cancer Research UK
Developer Alliance for Clinical Trials in Oncology; Bristol-Myers Squibb; Cancer Research UK; Clovis Oncology; Clovis Oncology [CEASED]; Merck Sharp & Dohme; National Cancer Institute (USA); NHS Greater Glasgow and Clyde; Roche; UNICANCER; University of Colorado at Denver; University of Oklahoma; University of Utah
Class 3-ring heterocyclic compounds; Amines; Antineoplastics; Azepines; Fluorine compounds; Indoles; Small molecules
Mechanism of Action Poly(ADP-ribose) polymerase 2 inhibitors; Poly(ADP-ribose) polymerase 3 inhibitors; Poly(ADP-ribose) polymerase-1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Ovarian cancer
New Molecular Entity Yes

Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer
Phase II Breast cancer; Cervical cancer; Endometrial cancer; Gastric cancer; Malignant-mesothelioma; Pancreatic cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
Phase I/II Non-small cell lung cancer
Suspended Malignant melanoma
No development reported Gynaecological cancer

10 Jan 2025 Bristol-Myers Squibb completes the phase II CheckMate 9KD trial for Prostate cancer (Combination therapy, Metastatic disease, Hormone refractory) in Argentina, Australia, Brazil, Canada, Chile, Colombia, France, Germany, Mexico, Spain, USA (PO) (NCT03338790) (EudraCT2017-001626-17)
24 Sep 2024 The pharma& Group enters into an exclusive promotional agreement with Tolmar to promote Rucaparib for the treatment of metastatic castration-resistant prostate cancer in USA
13 Sep 2024 Efficacy and adverse event data from a phase III trial in Ovarian cancer presented at 49th European Society for Medical Oncology Congress 2024 (ESMO-2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com